(AIM: SAR) 9 August 2018
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Sareum notes Sierra Oncology has reported Second Quarter Results
Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, has reported its Second Quarter Results including reference to the ongoing development of SRA737.
"We continue to advance our lead drug candidate, SRA737, across three distinct clinical development strategies; as a monotherapy, in combination with low dose gemcitabine, and in combination with a PARP inhibitor. During the second quarter, we further refined our monotherapy study to focus on high grade serous ovarian cancer (HGSOC), supported by emerging data in the field that provides clinical validation for Chk1 inhibition in this indication. Accordingly, we are prioritizing the enrollment of approximately 65 genetically defined HGSOC patients into this trial, while continuing to enroll patients into the trial's other indications, although with lower priority," said Dr. Nick Glover, President and CEO of Sierra Oncology. "However, given that this amendment will require time to operationalize, we anticipate preliminary data from our monotherapy trial will be reported in the first half of 2019."
Sierra is now also planning to include and prioritize for ovarian cancer patients in its combination trial of SRA737 potentiated by low dose gemcitabine. The company recently reported having commenced the Cohort Expansion Phase 2 portion of this trial, which is targeting enrollment of 80 patients across four indications. Sierra plans to modify this study to add and prioritize enrollment for a cohort of 20 genetically defined HGSOC patients, replacing an originally proposed cohort of urothelial cancer patients. Preliminary data from this trial is now also anticipated to be reported in the first half of 2019.
Title of announcement: Sierra Oncology Reports Second Quarter Results
Link to announcement: https://www.prnewswire.com/news-releases/sierra-oncology-reports-second-quarter-results-300694220.html
For further information, please contact:
Sareum Holdings plc |
|
Tim Mitchell |
01223 497 700 |
WH Ireland Limited (Nominated Adviser) |
Chris Fielding / James Sinclair-Ford |
020 7220 1666 |
Hybridan LLP (Broker) |
|
Claire Noyce |
020 3764 2341 |
Citigate Dewe Rogerson (Media enquiries) |
|
Shabnam Bashir/ Mark Swallow/ David Dible |
020 7638 9571 |
Notes for editors:
About Sareum
Sareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Its most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and in Phase 1/2 clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted monotherapy and in combination with other oncology and immuno-oncology drugs in genetically defined patients.
Sareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the candidate selection and IND-enabling preclinical stages.
The Company's drug discovery technology platform (SKIL® - Sareum Kinase Inhibitor Library) has the potential to generate drug research programmes against other kinase targets.
Sareum Holdings plc is quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk.
- Ends -
